Pfizer (PFE) is planning to sweeten its offer again for Metsera (MTSR), the weight-loss drug startup at the center of a bidding war that also involves Novo Nordisk (NVO), The Wall Street Journal’s Lauren Thomas and Jonathan Rockoff report. Pfizer is making plans to deliver a fresh bid Wednesday, according to people familiar with the matter, ahead of a deadline it has to respond to Novo Nordisk’s latest proposal. Under the terms of its existing merger agreement with Metsera, Pfizer’s next likely step is to match Novo Nordisk’s offer, one of the people said.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Pfizer says ‘we remain confident in the merits of our claims’ against Metsera
- Novo Nordisk tells STAT Metsera deal structure ‘consistent with antitrust laws’
- Metsera says will accept superior bids until closing, Bloomberg reports
- Metsera falls after FTC raises filing concerns over Novo bid
- 3 Best Dividend Aristocrat Stocks to Buy Now, 11/05/2025